Equillium Inc (EQ)

NASDAQ:EQ

Equillium

RESEARCH TOOLSreports

Want to see EQ full AI Analyst Report?

Equillium (EQ) Price & Analysis

791 Followers

EQ Stock Chart & Stats

$2.05

-$0.05(-6.85%)

At close: Jan 08 4:00 PM EST

$2.05

-$0.05(-6.85%)

Day’s Range― - ―

52-Week Range$0.27 - $2.70

Previous CloseN/A

Volume484.47K

Average Volume (3M)883.61K

Market Cap

$133.41M

Enterprise Value$45.39M

Total Cash (Recent Filing)$30.28M

Total Debt (Recent Filing)$719.00K

Price to Earnings (P/E)―

Beta-0.32

Next Earnings

Aug 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.56

Shares Outstanding63,226,555

10 Day Avg. Volume862,141

30 Day Avg. Volume883,611

Financial Highlights & Ratios

PEG Ratio-0.09

Price to Book (P/B)4.98

Price to Sales (P/S)1095.50

P/FCF Ratio-6.25

Enterprise Value/Market Cap0.34

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-391.31

Enterprise Value/Ebitda-1.96

Forecast

1Y Price Target

$7.67

Price Target Upside273.98% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-0.22

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Development StrategyPhase 1 will assess colon tissue biomarkers that previously predicted remission, and matching those biomarker levels could enable bridging to earlier efficacy signals and streamline development.

Mechanism ValidationClinical precedent for aryl hydrocarbon receptor modulation and independent drug data showing similar immune signals reduce mechanism risk for EQ504 as an anti-inflammatory approach.

Targeted Drug DeliveryAn enteric-coated, colon-targeted oral formulation is designed to boost local tissue exposure and potency while minimizing systemic exposure, which could improve therapeutic effect in the gut.

Bears Say

Bridging And Manufacturing RiskBatch variability and poor solubility in the validating botanical complicate reliance on historical data for regulatory bridging and raise comparability concerns with the optimized compound.

Clinical RiskPreclinical status of EQ504 increases development risk because human safety, optimal dosing, and clinical efficacy remain unproven.

Safety Legacy From BotanicalThe original botanical exhibited a systemic safety signal that halted a trial, so systemic safety concerns persist until colon-targeted delivery clearly mitigates those risks.

Equillium News

Equillium initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Equillium (EQ) with an Outperform rating and $7 price target The firm is positive...

18d ago

Equillium initiated with a Buy at B. Riley

B. Riley analyst William Wood initiated coverage of Equillium (EQ) with a Buy rating and $6 price target...

25d ago

Equillium initiated with a Strong Buy at Raymond James

Raymond James initiated coverage of Equillium (EQ) with a Strong Buy rating and $6 price target Lead asset...

28d ago

Equillium files to sell 18.88M shares of common stock for holders

17:14 EDT Equillium (EQ) files to sell 18.88M shares of common stock for holders Published first on TheFly...

1M ago

Cantor starts Equillium at Overweight on ulcerative colitis potential

Cantor Fitzgerald initiated coverage of Equillium (EQ) with an Overweight rating and $10 price target The company’s lead...

1M ago

Equillium initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Equillium (EQ) with an Overweight rating and $10 price target Published first on...

1M ago

Equillium reports Q4 EPS (4c), consensus (6c)

Cash, cash equivalents and short-term investments totaled $30.3M as of December 31, 2025, compared to $22.6M as of...

2M ago

EQ Upcoming Earnings Report: What to Expect?

Equillium (EQ) is scheduled to report 4th quarter earnings on 03/26/2026. Regarding Q4 estimates, Wall Street analysts expect...

2M ago

Equillium Raises Capital Through Private Equity Securities Sale

Equillium ( ($EQ) ) just unveiled an announcement. On March 11, 2026, Equillium, Inc. entered into a securities...

2M ago

Equillium announces $35M financing with RA Capital Management

Equillium (EQ) announced that it has entered into a definitive securities purchase agreement with RA Capital Management that...

2M ago

Equillium initiated with a Buy at Roth Capital

Roth Capital initiated coverage of Equillium (EQ) with a Buy rating and $12 price target The company’s EQ504...

2M ago

Equillium initiated with a Buy at Stifel

Stifel analyst Alex Thompson initiated coverage of Equillium (EQ) with a Buy rating and $5 price target Despite...

3M ago

Equillium Reports Q3 Loss Amid Strategic Focus

Equillium ( ($EQ) ) has released its Q3 earnings. Here is a breakdown of the information Equillium presented...

6M ago

Equillium Announces Board Restructuring and Biocon Agreement Termination

The latest update is out from Equillium ( ($EQ) ). On September 30, 2025, Equillium announced significant changes...

7M ago

EQ FAQ

What was Equillium Inc’s price range in the past 12 months?

Equillium Inc lowest stock price was $0.27 and its highest was $2.70 in the past 12 months.

What is Equillium Inc’s market cap?

Equillium Inc’s market cap is $133.41M.

When is Equillium Inc’s upcoming earnings report date?

Equillium Inc’s upcoming earnings report date is Aug 12, 2026 which is in 93 days.

How were Equillium Inc’s earnings last quarter?

Currently, no data Available

Is Equillium Inc overvalued?

According to Wall Street analysts Equillium Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Equillium Inc pay dividends?

Equillium Inc does not currently pay dividends.

What is Equillium Inc’s EPS estimate?

Equillium Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Equillium Inc have?

Equillium Inc has 63,226,555 shares outstanding.

What happened to Equillium Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Equillium Inc?

Currently, no hedge funds are holding shares in EQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Equillium Stock Smart Score

Neutral

Fundamentals

Return on Equity

-119.19%

Trailing 12-Months

Asset Growth

24.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Equillium Inc

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Equillium (EQ) Earnings & Revenues

Historic Earnings Reports

EQ Stock 12 Month Forecast

Average Price Target

$7.67

▲(273.98% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","13":"$13","-1":"-$1","2.5":"$2.5","9.5":"$9.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.666666666666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2.5,6,9.5,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.08,2.8430769230769233,3.6061538461538465,4.36923076923077,5.132307692307693,5.895384615384616,6.658461538461538,7.421538461538462,8.184615384615384,8.947692307692307,9.71076923076923,10.473846153846154,11.236923076923077,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.08,2.50974358974359,2.9394871794871795,3.3692307692307697,3.798974358974359,4.228717948717949,4.658461538461539,5.088205128205129,5.517948717948718,5.947692307692308,6.377435897435898,6.8071794871794875,7.236923076923078,{"y":7.666666666666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.08,2.3046153846153845,2.5292307692307694,2.753846153846154,2.9784615384615387,3.203076923076923,3.4276923076923076,3.6523076923076925,3.876923076923077,4.101538461538461,4.326153846153846,4.55076923076923,4.775384615384615,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.41,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.366,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.315,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.51,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >